We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Jazz Pharmaceuticals (JAZZ - Free Report) reported third-quarter 2024 adjusted earnings of $6.61 per share, which beat the Zacks Consensus Estimate of $5.47. Earnings rose 37% year over year.
Total revenues rose 9% year over year to $1.05 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.04 billion.
Shares of Jazz were up 2% in yesterday’s after-market trading session, likely due to the better-than-expected earnings.
The stock fell 9.3% year to date compared with the industry’s 3.5% decline.
Image Source: Zacks Investment Research
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
More on JAZZ’s Earnings
Net product sales rose 5% year over year at $989.7 million. The reported figure beat the Zacks Consensus Estimate and our model estimates of $976 million and $971 million, respectively.
Jazz recorded royalty revenues from high-sodium oxybate authorized generic (AG) of $58.2 million, which was twice the figure generated in the year-ago period. While the metric was in line with our model estimates, it beat the Zacks Consensus Estimate of $57 million.
Other royalties and contract revenues rose 47% to $7.1 million in the quarter.
JAZZ’s Neuroscience Segment
Sales of Jazz’s neuroscience products rose 4% to $702.7 million.
Net product sales for the combined oxybate business (Xyrem + Xywav) fell 2% to $446.6 million in the quarter. This combined revenue figure beat the Zacks Consensus Estimate of $431 million and our model estimates of $430 million.
Sales of the sleep disorder drug Xyrem plunged 54% year over year to $58.1 million due to patients switching to Xywav and the launch of AGs last year.
Xywav, a low-sodium formulation of Xyrem, recorded sales of $388.5 million in the quarter, up 17% year over year. This upside can be attributed to the encouraging uptake of the drug in narcolepsy and idiopathic hypersomnia (IH) indications. This drug is currently Jazz’s most extensive product by net sales.
Sales of the epilepsy drug Epidiolex/Epidyolex rose 18% to $251.6 million, likely driven by geographic expansion in ex-U.S. markets. Epidiolex sales beat the Zacks Consensus Estimate and our model estimates of $248 million and $245 million, respectively.
Cannabis-based mouth spray Sativex recorded sales of $4.6 million in the quarter, down 1% year over year.
JAZZ’s Oncology Segment
Oncology product sales increased 9% to $284.8 million.
Chemotherapy drug Rylaze/Enrylaze added sales of $98.8 million in the quarter, down 6% year over year. The drug’s sales were negatively impacted due to a recent update to pediatric acute lymphoblastic leukemia (ALL) protocols regarding the timing of asparaginase administration. Management expects this to affect ongoing demand. The company expects revenues to normalize by early 2025.
Rylaze sales missed the Zacks Consensus Estimate and our model estimates of $114 million and $115 million, respectively.
Zepzelca, approved for small cell lung cancer, recorded sales worth $85.8 million in the quarter, up 10% year over year.
Acute myeloid leukemia drug Vyxeos generated sales of $34.3 million, up 15% from the year-ago period’s levels.
Defitelio sales rose 38% year over year to $65.8 million in the quarter.
Discussion on JAZZ’s Operating Costs
Adjusted selling, general and administrative (SG&A) expenses were up 6% year over year at $288.7 million due to an increase in employee compensation-related expenses.
Adjusted research and development (R&D) expenses down 17% to $181 million, primarily due to a decline in clinical program costs.
JAZZ’s 2024 Guidance
While Jazz reiterated its overall revenue guidance for 2024, the company lowered its revenue prediction for sales in the Oncology franchise.
Total revenues are anticipated to be in the range of $4-$4.1 billion. The Oncology franchise is expected to record sales in the range of $1.08-$1.13 billion, down from the previous guidance of $1.10-$1.15 billion.
Management maintained its revenue prediction for neuroscience sales in the range of $2.83-$2.93 billion. This guidance also includes royalty revenues from high-sodium oxybate AG, which are expected to cross $200 million.
The company also revised its previously issued EPS guidance. Adjusted earnings are now expected to be in the range of $19.50-$20.60 per share, up from the previous guidance of $19.20-$20.30, primarily driven by strategic pipeline prioritization.
While adjusted SG&A expenses are anticipated to be in the range of $1.19-$1.23 billion (maintained), adjusted R&D expenses are expected in the band of $790-$830 million (previously: $810-$850 million).
In the past 60 days, estimates for Amicus Therapeutics’ 2024 EPS have moved up from 21 cents to 22 cents. EPS estimates for 2025 have increased from 49 cents to 53 cents during the same period. Year to date, shares of FOLD have lost 17.3%.
FOLD’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 23.96%.
In the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. During the same timeframe, loss estimates for 2025 have improved from $4.98 to $4.94. Year to date, shares of CRSP have lost 19.6%.
CRISPR Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 100.64%.
In the past 60 days, estimates for Biogen’s 2024 EPS have increased from $16.12 to $16.37. EPS estimates for 2025 have improved from $17.09 to $17.15. Year to date, shares of BIIB have lost 31.6%.
Biogen’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 9.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
Jazz Pharmaceuticals (JAZZ - Free Report) reported third-quarter 2024 adjusted earnings of $6.61 per share, which beat the Zacks Consensus Estimate of $5.47. Earnings rose 37% year over year.
Total revenues rose 9% year over year to $1.05 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.04 billion.
Shares of Jazz were up 2% in yesterday’s after-market trading session, likely due to the better-than-expected earnings.
The stock fell 9.3% year to date compared with the industry’s 3.5% decline.
Image Source: Zacks Investment Research
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
More on JAZZ’s Earnings
Net product sales rose 5% year over year at $989.7 million. The reported figure beat the Zacks Consensus Estimate and our model estimates of $976 million and $971 million, respectively.
Jazz recorded royalty revenues from high-sodium oxybate authorized generic (AG) of $58.2 million, which was twice the figure generated in the year-ago period. While the metric was in line with our model estimates, it beat the Zacks Consensus Estimate of $57 million.
Other royalties and contract revenues rose 47% to $7.1 million in the quarter.
JAZZ’s Neuroscience Segment
Sales of Jazz’s neuroscience products rose 4% to $702.7 million.
Net product sales for the combined oxybate business (Xyrem + Xywav) fell 2% to $446.6 million in the quarter. This combined revenue figure beat the Zacks Consensus Estimate of $431 million and our model estimates of $430 million.
Sales of the sleep disorder drug Xyrem plunged 54% year over year to $58.1 million due to patients switching to Xywav and the launch of AGs last year.
Xywav, a low-sodium formulation of Xyrem, recorded sales of $388.5 million in the quarter, up 17% year over year. This upside can be attributed to the encouraging uptake of the drug in narcolepsy and idiopathic hypersomnia (IH) indications. This drug is currently Jazz’s most extensive product by net sales.
Sales of the epilepsy drug Epidiolex/Epidyolex rose 18% to $251.6 million, likely driven by geographic expansion in ex-U.S. markets. Epidiolex sales beat the Zacks Consensus Estimate and our model estimates of $248 million and $245 million, respectively.
Cannabis-based mouth spray Sativex recorded sales of $4.6 million in the quarter, down 1% year over year.
JAZZ’s Oncology Segment
Oncology product sales increased 9% to $284.8 million.
Chemotherapy drug Rylaze/Enrylaze added sales of $98.8 million in the quarter, down 6% year over year. The drug’s sales were negatively impacted due to a recent update to pediatric acute lymphoblastic leukemia (ALL) protocols regarding the timing of asparaginase administration. Management expects this to affect ongoing demand. The company expects revenues to normalize by early 2025.
Rylaze sales missed the Zacks Consensus Estimate and our model estimates of $114 million and $115 million, respectively.
Zepzelca, approved for small cell lung cancer, recorded sales worth $85.8 million in the quarter, up 10% year over year.
Acute myeloid leukemia drug Vyxeos generated sales of $34.3 million, up 15% from the year-ago period’s levels.
Defitelio sales rose 38% year over year to $65.8 million in the quarter.
Discussion on JAZZ’s Operating Costs
Adjusted selling, general and administrative (SG&A) expenses were up 6% year over year at $288.7 million due to an increase in employee compensation-related expenses.
Adjusted research and development (R&D) expenses down 17% to $181 million, primarily due to a decline in clinical program costs.
JAZZ’s 2024 Guidance
While Jazz reiterated its overall revenue guidance for 2024, the company lowered its revenue prediction for sales in the Oncology franchise.
Total revenues are anticipated to be in the range of $4-$4.1 billion. The Oncology franchise is expected to record sales in the range of $1.08-$1.13 billion, down from the previous guidance of $1.10-$1.15 billion.
Management maintained its revenue prediction for neuroscience sales in the range of $2.83-$2.93 billion. This guidance also includes royalty revenues from high-sodium oxybate AG, which are expected to cross $200 million.
The company also revised its previously issued EPS guidance. Adjusted earnings are now expected to be in the range of $19.50-$20.60 per share, up from the previous guidance of $19.20-$20.30, primarily driven by strategic pipeline prioritization.
While adjusted SG&A expenses are anticipated to be in the range of $1.19-$1.23 billion (maintained), adjusted R&D expenses are expected in the band of $790-$830 million (previously: $810-$850 million).
JAZZ’s Zacks Rank
Jazz currently has a Zacks Rank #3 (Hold).
Jazz Pharmaceuticals PLC Price
Jazz Pharmaceuticals PLC price | Jazz Pharmaceuticals PLC Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Amicus Therapeutics (FOLD - Free Report) , Biogen (BIIB - Free Report) and CRISPR Therapeutics (CRSP - Free Report) . While FOLD and CRSP each sports a Zacks Rank #1 (Strong Buy) at present, BIIB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Amicus Therapeutics’ 2024 EPS have moved up from 21 cents to 22 cents. EPS estimates for 2025 have increased from 49 cents to 53 cents during the same period. Year to date, shares of FOLD have lost 17.3%.
FOLD’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 23.96%.
In the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. During the same timeframe, loss estimates for 2025 have improved from $4.98 to $4.94. Year to date, shares of CRSP have lost 19.6%.
CRISPR Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 100.64%.
In the past 60 days, estimates for Biogen’s 2024 EPS have increased from $16.12 to $16.37. EPS estimates for 2025 have improved from $17.09 to $17.15. Year to date, shares of BIIB have lost 31.6%.
Biogen’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 9.99%.